Clinical Trials Resource Center


January 31, 2011

R-Tech Ueno reported results from a phase IIa trial of RK-023 for the treatment of alopecia. The double blind, placebo-controlled study enrolled 48 adult males (aged 44 years and younger) with mild-to-moderate androgenetic alopecia. The subjects trial applied RK-023 2 mL each to a hair-thinning part of scalp twice daily for 13 consecutive weeks. Endpoints included safety, pharmacokinetics and pharnacodynamics and the presence of anagen hair, defined as hair with a growth rate of 0.2 mm or more per day through phototrichogram. There were no reports of serious adverse events. Adverse events were similar between the RK-023 and placebo treatment arms. The main metabolite of RK-023 was slightly detected in plasma of only one subject, showing that the transdermal absorption of RK-023 from the scalp was low. In the efficacy assessment, the RK-023 group showed possibility of improvement in global photo assessment and in numbers of anagen hair from the baseline compared with the placebo group.

Related Medical Areas

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.